A  ||| S:0 E:2 ||| DT
stepwise  ||| S:2 E:11 ||| JJ
approach  ||| S:11 E:20 ||| NN
to  ||| S:20 E:23 ||| TO
justify  ||| S:23 E:31 ||| VB
phase  ||| S:31 E:37 ||| NN
III  ||| S:37 E:41 ||| NNP
randomized  ||| S:41 E:52 ||| VBD
clinical  ||| S:52 E:61 ||| JJ
trials  ||| S:61 E:68 ||| NNS
and  ||| S:68 E:72 ||| CC
enhance  ||| S:72 E:80 ||| VB
the  ||| S:80 E:84 ||| DT
likelihood  ||| S:84 E:95 ||| NN
of  ||| S:95 E:98 ||| IN
a  ||| S:98 E:100 ||| DT
positive  ||| S:100 E:109 ||| JJ
result  ||| S:109 E:116 ||| NN
Multiple  ||| S:116 E:125 ||| NNP
time-consuming ||| S:125 E:139 ||| JJ
,  ||| S:139 E:141 ||| ,
expensive ||| S:141 E:150 ||| JJ
,  ||| S:150 E:152 ||| ,
and  ||| S:152 E:156 ||| CC
negative  ||| S:156 E:165 ||| JJ
phase  ||| S:165 E:171 ||| NN
III  ||| S:171 E:175 ||| NNP
clinical  ||| S:175 E:184 ||| JJ
trials  ||| S:184 E:191 ||| NNS
involving  ||| S:191 E:201 ||| VBG
many  ||| S:201 E:206 ||| JJ
thousands  ||| S:206 E:216 ||| NNS
of  ||| S:216 E:219 ||| IN
patients  ||| S:219 E:228 ||| NNS
have  ||| S:228 E:233 ||| VBP
been  ||| S:233 E:238 ||| VBN
undertaken  ||| S:238 E:249 ||| VBN
in  ||| S:249 E:252 ||| IN
critical  ||| S:252 E:261 ||| JJ
care  ||| S:261 E:266 ||| NN
and  ||| S:266 E:270 ||| CC
continue  ||| S:270 E:279 ||| VB
to  ||| S:279 E:282 ||| TO
be  ||| S:282 E:285 ||| VB
funded ||| S:285 E:291 ||| VBN
.  ||| S:291 E:293 ||| .
The  ||| S:293 E:297 ||| DT
vast  ||| S:297 E:302 ||| JJ
majority  ||| S:302 E:311 ||| NN
of  ||| S:311 E:314 ||| IN
these  ||| S:314 E:320 ||| DT
clinical  ||| S:320 E:329 ||| JJ
trials  ||| S:329 E:336 ||| NNS
are  ||| S:336 E:340 ||| VBP
negative ||| S:340 E:348 ||| JJ
.  ||| S:348 E:350 ||| .
Furthermore ||| S:350 E:361 ||| RB
,  ||| S:361 E:363 ||| ,
phase  ||| S:363 E:369 ||| NN
III  ||| S:369 E:373 ||| NNP
studies  ||| S:373 E:381 ||| NNS
frequently  ||| S:381 E:392 ||| RB
fail  ||| S:392 E:397 ||| VB
to  ||| S:397 E:400 ||| TO
achieve  ||| S:400 E:408 ||| VB
their  ||| S:408 E:414 ||| PRP$
planned  ||| S:414 E:422 ||| JJ
recruitment  ||| S:422 E:434 ||| JJ
target ||| S:434 E:440 ||| NN
.  ||| S:440 E:442 ||| .
Often  ||| S:442 E:448 ||| RB
such  ||| S:448 E:453 ||| JJ
studies  ||| S:453 E:461 ||| NNS
are  ||| S:461 E:465 ||| VBP
based  ||| S:465 E:471 ||| VBN
on  ||| S:471 E:474 ||| IN
small  ||| S:474 E:480 ||| JJ
pilot  ||| S:480 E:486 ||| NN
studies  ||| S:486 E:494 ||| NNS
with  ||| S:494 E:499 ||| IN
inadequate  ||| S:499 E:510 ||| JJ
phase  ||| S:510 E:516 ||| NN
II  ||| S:516 E:519 ||| NNP
trial  ||| S:519 E:525 ||| NN
data  ||| S:525 E:530 ||| NNS
and  ||| S:530 E:534 ||| CC
limited  ||| S:534 E:542 ||| JJ
mechanistic  ||| S:542 E:554 ||| JJ
data  ||| S:554 E:559 ||| NNS
to  ||| S:559 E:562 ||| TO
provide  ||| S:562 E:570 ||| VB
a  ||| S:570 E:572 ||| DT
sound  ||| S:572 E:578 ||| JJ
scientific  ||| S:578 E:589 ||| JJ
rationale ||| S:589 E:598 ||| NN
.  ||| S:598 E:600 ||| .
The  ||| S:600 E:604 ||| DT
body  ||| S:604 E:609 ||| NN
of  ||| S:609 E:612 ||| IN
research  ||| S:612 E:621 ||| NN
required  ||| S:621 E:630 ||| VBN
to  ||| S:630 E:633 ||| TO
justify  ||| S:633 E:641 ||| VB
undertaking  ||| S:641 E:653 ||| VBG
a  ||| S:653 E:655 ||| DT
phase  ||| S:655 E:661 ||| NN
III  ||| S:661 E:665 ||| NNP
trial  ||| S:665 E:671 ||| NN
in  ||| S:671 E:674 ||| IN
the  ||| S:674 E:678 ||| DT
critically  ||| S:678 E:689 ||| JJ
ill  ||| S:689 E:693 ||| JJ
population  ||| S:693 E:704 ||| NN
has  ||| S:704 E:708 ||| VBZ
not  ||| S:708 E:712 ||| RB
been  ||| S:712 E:717 ||| VBN
defined  ||| S:717 E:725 ||| VBN
adequately ||| S:725 E:735 ||| RB
.  ||| S:735 E:737 ||| .
In  ||| S:737 E:740 ||| IN
particular ||| S:740 E:750 ||| JJ
,  ||| S:750 E:752 ||| ,
guidance  ||| S:752 E:761 ||| NN
on  ||| S:761 E:764 ||| IN
the  ||| S:764 E:768 ||| DT
design  ||| S:768 E:775 ||| NN
of  ||| S:775 E:778 ||| IN
phase  ||| S:778 E:784 ||| NN
II  ||| S:784 E:787 ||| NNP
studies  ||| S:787 E:795 ||| NNS
for  ||| S:795 E:799 ||| IN
evaluating  ||| S:799 E:810 ||| VBG
treatments  ||| S:810 E:821 ||| NNS
in  ||| S:821 E:824 ||| IN
the  ||| S:824 E:828 ||| DT
critically  ||| S:828 E:839 ||| JJ
ill  ||| S:839 E:843 ||| JJ
population  ||| S:843 E:854 ||| NN
is  ||| S:854 E:857 ||| VBZ
needed ||| S:857 E:863 ||| VBN
.  ||| S:863 E:865 ||| .
Research  ||| S:865 E:874 ||| NN
to  ||| S:874 E:877 ||| TO
inform  ||| S:877 E:884 ||| VB
critical  ||| S:884 E:893 ||| JJ
care  ||| S:893 E:898 ||| NN
practice  ||| S:898 E:907 ||| NN
will  ||| S:907 E:912 ||| MD
progress  ||| S:912 E:921 ||| VB
more  ||| S:921 E:926 ||| RBR
efficiently  ||| S:926 E:938 ||| RB
and  ||| S:938 E:942 ||| CC
effectively  ||| S:942 E:954 ||| RB
if  ||| S:954 E:957 ||| IN
this  ||| S:957 E:962 ||| DT
can  ||| S:962 E:966 ||| MD
be  ||| S:966 E:969 ||| VB
achieved ||| S:969 E:977 ||| VBN
.  ||| S:977 E:979 ||| .
The  ||| S:979 E:983 ||| DT
following  ||| S:983 E:993 ||| JJ
article  ||| S:993 E:1001 ||| NN
presents  ||| S:1001 E:1010 ||| VBZ
a  ||| S:1010 E:1012 ||| DT
template  ||| S:1012 E:1021 ||| NN
on  ||| S:1021 E:1024 ||| IN
the  ||| S:1024 E:1028 ||| DT
minimum  ||| S:1028 E:1036 ||| JJ
evidence  ||| S:1036 E:1045 ||| NN
required  ||| S:1045 E:1054 ||| VBN
to  ||| S:1054 E:1057 ||| TO
justify  ||| S:1057 E:1065 ||| VB
phase  ||| S:1065 E:1071 ||| NN
III  ||| S:1071 E:1075 ||| NNP
clinical  ||| S:1075 E:1084 ||| JJ
trials  ||| S:1084 E:1091 ||| NNS
in  ||| S:1091 E:1094 ||| IN
the  ||| S:1094 E:1098 ||| DT
critically  ||| S:1098 E:1109 ||| JJ
ill  ||| S:1109 E:1113 ||| JJ
population ||| S:1113 E:1123 ||| NN
.  ||| S:1123 E:1125 ||| .
